{"product_id":"bdx-bcg-matrix","title":"(BDX) Becton, Dickinson and Company BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Becton, Dickinson and Company BCG Matrix is a ready-made analysis that helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual deliverable, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD MAX and BD COR molecular diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD MAX and BD COR fit the Stars quadrant because they sit in the PCR infectious-disease market, which is projected to top $20 billion by 2026. BD already has a global clinical-lab installed base, so each new placement can drive recurring reagent sales and lift pull-through. If placements keep rising, this platform can stay high-share and high-growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD FACSymphony cell analysis systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD FACSymphony cell analysis systems fit the Star bucket because high-end flow cytometry and single-cell research are still growing fast, and BD’s brand is strong in immunology workflows. BD reported about $21.8 billion in fiscal 2025 revenue, showing the scale behind this platform. The installed base drives recurring reagent and service sales, which supports repeat cash flow and keeps growth sticky.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePyxis medication management systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePyxis medication management systems fit the Stars quadrant: hospital automation is gaining fast as pharmacies digitize, and BD can scale through its broad acute-care footprint. In BD’s FY2025, sales were about $21.8 billion, giving it the reach to push software, dispensing automation, and connected-care upgrades across hospitals. If adoption keeps rising, Pyxis can turn that base into faster recurring software and service growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrefillable syringes for biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrefillable syringes for biologics stay a Star for Becton, Dickinson and Company because biologics keep growing and every new injectable needs high-spec delivery parts. BD’s pharma solutions business benefits from tight validation, sterile fill-finish needs, and switching costs, which supports pricing power. In FY2025, BD generated about $21.8B in revenue, showing the scale behind this platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-complexity, regulated demand\u003c\/li\u003e\n\u003cli\u003eSticky pharma customer base\u003c\/li\u003e\n\u003cli\u003eSupports margin and growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvanced vascular access catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced vascular access catheters are a Star for Becton, Dickinson and Company because infection-control and workflow gains matter more in acute care, and hospitals keep standardizing higher-use IV products. Becton, Dickinson and Company reported about $21.8 billion in fiscal 2025 revenue, and its IV access and vascular-care systems give it scale in a category tied to rising procedure volumes. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong fit with hospital standardization\u003c\/li\u003e\n\u003cli\u003eSupports infection-control goals\u003c\/li\u003e\n\u003cli\u003eBenefits from high acute-care use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD’s Growth Stars: High-Margin Platforms Powering Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBecton, Dickinson and Companys Stars are BD MAX and BD COR, BD FACSymphony, Pyxis, prefillable syringes, and advanced vascular access. These units sit in high growth, high stickiness markets, and BD reported about $21.8 billion in fiscal 2025 revenue, giving scale to push placements, consumables, and services.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD MAX\u003c\/td\u003e\n\u003ctd\u003ePCR growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePyxis\u003c\/td\u003e\n\u003ctd\u003eAutomation demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix overview of Becton, Dickinson’s portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with clear invest\/hold\/divest cues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Becton, Dickinson and Company to quickly spot pain points and growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear, traceable source trail for Becton, Dickinson and Company, boosting credibility and speeding confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHypodermic syringes and needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHypodermic syringes and needles sit in a mature, very high-volume market, and Becton, Dickinson and Company is one of the best-known global suppliers. BD’s annual revenue is about $20 billion, showing the scale behind this cash cow. Demand stays steady because hospitals and clinics keep replacing stock, so cash generation is recurring and reliable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard peripheral IV catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard peripheral IV catheters are short-dwell devices, usually used for 1-4 days, and they are one of the most common hospital consumables. Becton, Dickinson and Company’s broad distribution and entrenched hospital ties support repeat orders at scale. In a mature category with low promo spend, this line can generate steady cash flow, which fits a Cash Cow in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood collection tubes and needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlood collection tubes and needles fit BD’s Cash Cows: specimen collection is a high-volume, low-growth lab consumable, and BD benefits from repeat use plus long-term hospital and lab contracts. This steady base helps fund larger bets elsewhere, while BD’s FY2025 revenue was about $20 billion, showing the scale of cash generation behind these routine products. In a market where demand is tied to daily testing, not fast growth, this category stays dependable and highly cash rich.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeedle-free connectors and closed-system transfer devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeedle-free connectors and closed-system transfer devices are classic cash cows for Becton, Dickinson and Company: they are recurring infection-prevention consumables tied to inpatient protocols, so switching is low and share retention is strong. The CDC says 1 in 31 U.S. hospital patients has at least one healthcare-associated infection on any day, which keeps demand firm.\u003c\/p\u003e\n\u003cp\u003eBecause the market is mature, growth is modest, but volume is steady and margins are usually more cash-generative than expansion-driven. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring use in inpatient care\u003c\/li\u003e\n\u003cli\u003eEmbedded in hospital protocols\u003c\/li\u003e\n\u003cli\u003eLow switching, strong retention\u003c\/li\u003e\n\u003cli\u003eMature market, steady cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoutine microbiology consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoutine microbiology consumables are a classic cash cow: plated media and standard lab items are replenished again and again, so demand stays steady even when growth is slow.\u003c\/p\u003e\n\u003cp\u003eBD’s large installed base in clinical labs supports durable share, and its FY2025 revenue was about $20 billion, with this franchise helping convert volume into recurring cash flow.\u003c\/p\u003e\n\u003cp\u003eSo, this segment is not a high-growth engine, but it is a reliable profit and free-cash-flow source.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReplenishment-driven demand\u003c\/li\u003e\n\u003cli\u003eDurable lab share\u003c\/li\u003e\n\u003cli\u003eModest growth, steady cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD’s Cash Cow: A $20B Recurring Consumables Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD’s Cash Cows are mature, high-volume consumables like syringes, IV catheters, blood collection, and routine lab items. These products sell through repeat hospital and lab orders, so they generate steady cash even with low growth. BD’s FY2025 revenue was about $20 billion, underscoring the scale behind this recurring cash engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003eRepeat use, low switching\u003c\/td\u003e\n\u003ctd\u003eAbout $20B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eBecton, Dickinson and Company Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Becton, Dickinson and Company BCG Matrix preview on this page is the exact document you’ll receive after purchase. No demo text, no watermarks—just the complete, ready-to-use report. Once purchased, you’ll get the same professionally formatted file for immediate use in analysis, planning, or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic surgical instrumentation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBasic surgical instrumentation is a classic \"Dog\" for Becton, Dickinson and Company: commodity tools face heavy price pressure, weak differentiation, and slow growth in mature hospital channels. That makes returns thin and strategic upside limited, especially when buyers standardize on lowest-bid supply contracts. In Becton, Dickinson and Company's fiscal 2025 base, this kind of low-growth line fits a low-share, low-return profile rather than a core growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHernia and soft-tissue repair products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHernia and soft-tissue repair products sit in a mature, crowded market, so BD does not have the same pricing power or scale edge here as in consumables. Share gains are hard, margins stay under pressure, and this line can look like a low-growth Cash Cow at best, or a Dog if returns stay weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosurgery and bioresorbable grafts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiosurgery and bioresorbable grafts are still Dogs for Becton, Dickinson and Company: they are niche products with uneven adoption, and the fragmented market moves slower than diagnostics or automation. That limits scale economics, so gross margin leverage is weaker. In BD's FY2025 mix, these products remained a small, lower-speed surgical line versus the company’s larger core franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy urology and critical care devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy urology and critical care devices at Becton, Dickinson and Company fit the Dogs bucket: mature lines with low growth, pricing pressure, and tight procurement discipline from hospitals. The mix tends to improve only in small steps, so capital tied to these products often earns weak incremental returns. BD’s 2024 annual report still showed companywide revenue of $20.2 billion, but these older lines are not the main growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, heavy pricing pressure\u003c\/li\u003e\n\u003cli\u003eIncremental differentiation only\u003c\/li\u003e\n\u003cli\u003eCapital can earn weak returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePeripheral intervention legacy platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePeripheral intervention legacy platforms fit Dogs in Becton, Dickinson and Company’s BCG mix: the category is crowded, capital heavy, and BD is less dominant here than in needles or blood collection. In FY2025, Becton, Dickinson and Company reported about $21.7 billion in revenue, but these slower-growth lines likely add less pull if volumes stay flat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCrowded market, high capital needs\u003c\/li\u003e\n\u003cli\u003eWeaker share than core BD franchises\u003c\/li\u003e\n\u003cli\u003eMuted volume growth keeps returns low\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD’s FY2025 Dogs: Thin Margins, Low Growth, Weak Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Becton, Dickinson and Company’s FY2025 mix, Dogs are mostly legacy surgical, urology, and peripheral intervention lines: low growth, weak differentiation, and heavy price pressure. These niches sit in crowded hospital channels, so capital earns thin returns. BD’s FY2025 revenue was about $21.7 billion, but these lines add little growth pull.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog line\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy surgical\u003c\/td\u003e\n\u003ctd\u003eCommodity pricing\u003c\/td\u003e\n\u003ctd\u003eThin margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy urology\u003c\/td\u003e\n\u003ctd\u003eMature demand\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeripheral intervention\u003c\/td\u003e\n\u003ctd\u003eCrowded market\u003c\/td\u003e\n\u003ctd\u003eWeak share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD Rhapsody single-cell genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD Rhapsody sits in Question Marks: single-cell genomics is still a high-growth space, with market forecasts near mid- to high-teens CAGR through 2030, but BD faces bigger specialist rivals like 10x Genomics. The science case is strong, yet BD does not hold clear share leadership. Turning demand into scale will need heavy R\u0026amp;D, sales, and workflow investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced cell sorting and omics workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced cell sorting and omics workflows sit in a fast-growing niche: single-cell and multiomics spending is still rising at double-digit rates, but buyers want end-to-end platforms, software, and service support. BD has credible instruments and install base, yet rivals like Danaher and Thermo Fisher make this a crowded field. To win share, Becton, Dickinson and Company must keep funding product refreshes and stronger channel reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-enabled medication analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAI-enabled medication analytics fits the Question Marks bucket: hospitals want software that predicts med risk and optimizes inventory, but BD still trails software-native rivals on share. BD’s scale helps, with about $20.9B in FY2025 revenue, yet this is still a high-growth, not clearly dominant, play. The workflow base is real, but conversion to leadership is not proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRapid molecular assay expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRapid molecular assays are a Question Mark for Becton, Dickinson and Company: point-of-care testing is growing fast, but adoption is still uneven and rivals are crowded in. BD needs more placements, stronger clinical validation, and easier workflow proof to move this business from trial use to scale.\u003c\/p\u003e\n\u003cp\u003eThe opportunity is real, but the cash burn risk is too, so growth here depends on winning hospital trust and expanding test-site coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast growth, but uneven uptake\u003c\/li\u003e\n\u003cli\u003ePlacements and validation matter most\u003c\/li\u003e\n\u003cli\u003eCompetition stays intense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging lab automation in lower-penetration regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmerging lab automation in lower-penetration regions is a question mark for Becton, Dickinson and Company: demand is rising in mid-market and international labs, but share outside core accounts is still building. BD can lean on its installed base and brand, yet the segment still needs heavy investment to win new sites and defend margin, so it stays a clear invest-or-exit call.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemand is rising outside core accounts.\u003c\/li\u003e\n\u003cli\u003eShare is still early in many regions.\u003c\/li\u003e\n\u003cli\u003eInstalled base supports expansion.\u003c\/li\u003e\n\u003cli\u003eCapital needs stay high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD's High-Growth Bets Still Need Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks for Becton, Dickinson and Company are high-growth plays with weak share proof: BD Rhapsody, advanced cell sorting, AI med analytics, and rapid molecular assays all sit in crowded markets, while FY2025 revenue was $20.9B. They can scale if BD keeps funding R\u0026amp;D, placements, and channel reach, but each still needs stronger adoption and clearer leadership.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eFY2025\/FY2026 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD Rhapsody\u003c\/td\u003e\n\u003ctd\u003eHigh growth, low share\u003c\/td\u003e\n\u003ctd\u003eSingle-cell market ~mid\/high-teens CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI med analytics\u003c\/td\u003e\n\u003ctd\u003eScale helps, leadership unproven\u003c\/td\u003e\n\u003ctd\u003eRevenue $20.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRapid molecular assays\u003c\/td\u003e\n\u003ctd\u003eAdoption still uneven\u003c\/td\u003e\n\u003ctd\u003eCompetitive, capital-heavy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191779107081,"sku":"bdx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bdx-bcg-matrix.webp?v=1783678442","url":"https:\/\/dcfanalyst.com\/products\/bdx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}